keyword
MENU ▼
Read by QxMD icon Read
search

Von willebrands

keyword
https://www.readbyqxmd.com/read/29782255/-high-on-treatment-platelet-reactivity-determinants-on-dual-antiplatelet-therapy-in-patients-with-ischemic-heart-disease-before-elective-percutaneous-coronary-intervention
#1
E Z Golukhova, M V Grigoryan, M N Ryabinina, N I Bulaeva
OBJECTIVE: to determine impact of different laboratory and genetic factors on high on-treatment platelet reactivity (HOPR) during dual antiplatelet therapy (DAPT). METHODS: We included in this study 94 patients with stable ischemic heart disease (mean age 59±9.67 years). All patients underwent elective PCI with implantation of drug eluting stents at the background of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. Platelet reactivity was assessed using light transmission aggregometry with 5 μmol/L ADP (LTA 5ADP) and VerifyNow assay before PCI...
April 2018: Kardiologiia
https://www.readbyqxmd.com/read/29773546/kruse-jarres-r-johnsen-jm-how-i-treat-type-2b-von-willebrand-disease-blood-2018-131-12-1292-1300
#2
(no author information available yet)
No abstract text is available yet for this article.
May 17, 2018: Blood
https://www.readbyqxmd.com/read/29770800/current-and-future-circulating-biomarkers-for-cardiac-amyloidosis
#3
REVIEW
Marco Luciani, Luca Troncone, Federica Del Monte
Cardiac amyloidosis (CA) comprises a heterogeneous group of medical conditions affecting the myocardium. It presents with proteinaceous infiltration with variable degrees of severity, prevalence and evolution. Despite this heterogeneity, erroneous protein folding is the common pathophysiologic process, yielding the formation of a single misfolded protein (monomer) that progressively evolves and ultimately forms amyloid fibers. Additionally, by seeding out from the organs of origin, intermediates called oligomers metastasize and restart the process...
May 17, 2018: Acta Pharmacologica Sinica
https://www.readbyqxmd.com/read/29769425/gender-differences-in-hemostatic-and-inflammatory-factors-in-patients-with-acute-coronary-syndromes-a-pilot-study
#4
A Siennicka, M Jastrzebska, K Smialkowska, S Oledzki, K Chelstowski, M Klysz, J Clark, Z Kornacewicz-Jach
Many studies have shown gender differences in the progress of acute coronary syndromes (ACS). These differences include, amongst others, processes involved in hemostasis and inflammation, and in the present study we put forward the hypothesis that these are the primary cause of other differences. The study included 66 ACS patients (27 women and 39 men) aged 43 - 83 years, 23 with non-ST-elevation myocardial infarction (NSTEMI) and 43 with ST-elevation myocardial infarction (STEMI). Blood samples were taken on day 3 (NSTEMI) or day 5 (STEMI) after hospitalization, and fibrinogen, D-dimers, von Willebrand factor, C-reactive protein and interleukin-6 levels measured...
February 2018: Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society
https://www.readbyqxmd.com/read/29769259/novel-therapeutics-for-hemophilia-and-other-bleeding-disorders
#5
Michael U Callaghan, Robert Sidonio, Steven W Pipe
Hemophilia and von Willebrand disease are the most common congenital bleeding disorders. Treatment for these disorders has focused on replacement of the missing coagulation factor to prevent or treat bleeding. New technologies and insights into hemostasis have driven the development of many promising new therapies for hemophilia and von Willebrand disease. Emerging bypass agents including zymogen-like factor IXa and Xa molecules are in development and a bispecific antibody, emicizumab, demonstrated efficacy in a phase III trial in people with hemophilia A and inhibitors...
May 16, 2018: Blood
https://www.readbyqxmd.com/read/29767844/comorbidities-associated-with-higher-von-willebrand-factor-vwf-levels-may-explain-the-age-related-increase-of-vwf-in-von-willebrand-disease
#6
Ferdows Atiq, Karina Meijer, Jeroen Eikenboom, Karin Fijnvandraat, Eveline P Mauser-Bunschoten, Karin P M van Galen, Marten R Nijziel, Paula F Ypma, Joke de Meris, Britta A P Laros-van Gorkom, Johanna G van der Bom, Moniek P de Maat, Marjon H Cnossen, Frank W G Leebeek
Some comorbidities, such as hypertension, are associated with higher von Willebrand factor (VWF) levels in the general population. No studies have been conducted to assess this association in patients with von Willebrand disease (VWD). Therefore, we studied this association in patients with type 1 (n = 333) and type 2 (n = 203) VWD from the 'WiN" study. VWF antigen (VWF:Ag) was higher in type 1 VWD patients with hypertension [difference: 0·23 iu/ml, 95% confidence interval (CI): 0·11-0·35], diabetes mellitus (0·11 iu/ml, 95% CI: -0·02 to 0·23), cancer (0·14 iu/ml, 95% CI: 0·03-0·25) and thyroid dysfunction (0·14 iu/ml, 95% CI: 0·03-0·26) than in patients without these comorbidities (all corrected for age, sex and blood group)...
May 16, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29765290/extended-half-life-factor-viii-and-factor-ix-preparations
#7
REVIEW
Lukas Graf
In the last couple of years, several extended half-life factor VIII and factor IX preparations were intensively studied and gained approval. In order to extend half-lives, techniques like fusion to protein conjugates (Fc part of IgG1 or albumin), chemical modification (PEGylation), and protein sequence modification are implemented. With these techniques, it is possible to extend half-lives of factor IX products 4- to 6- fold, while half-life extension of factor VIII products is limited to 1.5- to 2-fold due to their interaction with von Willebrand factor...
April 2018: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/29761335/-biomarkers-and-atrial-fibrillation-prediction-of-recurrences-and-thromboembolic-events-after-rhythm-control-management
#8
REVIEW
Jelena Kornej, Katja Schumacher, Daniela Husser, Gerhard Hindricks
Atrial fibrillation (AF) is the most common arrhythmia in clinical praxis and is associated with an increased risk for cardio- and cerebrovascular complications leading to an increased mortality. Catheter ablation represents one of the most important and efficient therapy strategies in AF patients. Nevertheless, the high incidence of arrhythmia recurrences after catheter ablation leads to repeated procedures and higher treatment costs. Recently, several scores had been developed to predict rhythm outcomes after catheter ablation...
May 14, 2018: Herzschrittmachertherapie & Elektrophysiologie
https://www.readbyqxmd.com/read/29760727/expanded-cd133-cells-from-human-umbilical-cord-blood-improved-heart-function-in-rats-after-severe-myocardial-infarction
#9
Alejandro Correa, Gabriel Salles Ottoboni, Alexandra Cristina Senegaglia, Luiz Guilherme Achcar Capriglione, Nelson Itiro Miyague, Lidiane Maria Boldrini Leite, Valderez Ravaglio Jamur, Carmen Lúcia Kuniyoshi Rebelatto, Márcia Olandoski, Paulo Roberto Slud Brofman
Pharmacological approaches are partially effective in limiting infarct size. Cell therapies using a cell population enriched with endothelial progenitor cells (EPCs) CD133+ have opened new perspectives for the treatment of ischemic areas after infarction. This preclinical study evaluated the effect of intramyocardial transplantation of purified or expanded human umbilical cord blood-derived CD133+ cells on the recovery of rats following acute myocardial infarction (AMI). Histology studies, electrocardiogram, and fluorescence in situ hybridization (FISH) were used to evaluate heart recovery...
2018: Stem Cells International
https://www.readbyqxmd.com/read/29760619/adamts13-deficiency-and-immunological-abnormalities-in-patients-with-systemic-sclerosis
#10
Zofia Gerlicz-Kowalczuk, Jolanta D Torzecka, Elżbieta Dziankowska-Zaborszczyk, Alicja Ograczyk, Anna M Zalewska-Janowska, Anna Woźnicka, Bożena Dziankowska-Bartkowiak
Introduction: Systemic sclerosis (SSc) is a chronic autoimmune connective tissue disorder characterized by immunological deviations and generalized microvascular damage. Aim: To determine the serum level of the von Willebrand factor cleaving protease (ADAMTS13) in 39 SSc patients and healthy controls. Material and methods: ADAMTS13 serum level was determined in 39 SSc patients and 11 healthy controls. Complete history of the patients was recorded and thorough clinical, rheumatological, and dermatological examinations were performed...
April 2018: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/29754468/bleeding-score-in-type-1-von-willebrand-disease-patients-using-the-condensed-mcmdm-1-vwd-validated-questionnaire
#11
A Pathare, F Al Hajri, S Al Omrani, N Al Obaidani, B Al Balushi, K Al Falahi
BACKGROUND: Assessment of the severity of bleeding symptom has led to the evolution of bleeding assessment tools which are now validated. AIMS: To administer the condensed molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease VWD (MCMDM-1 vWD) questionnaire to the Omani type 1 vWD patients and correlate it with the laboratory parameters. METHODS: Patients and controls were personally interviewed and the condensed MCMDM-1 vWD questionnaire administered by a single investigator...
May 13, 2018: International Journal of Laboratory Hematology
https://www.readbyqxmd.com/read/29751951/biochemical-characterization-and-immunogenicity-of-neureight-a-recombinant-full-length-factor-viii-produced-by-fed-batch-process-in-disposable-bioreactors
#12
Sandrine Delignat, Ivan Peyron, Maria El Ghazaly, Srinivas V Kaveri, Jan Rohde, Frank Mueller, Sebastien Lacroix-Desmazes
Hemophilia A is a X-linked recessive bleeding disorder consecutive to the lack of circulating pro-coagulant factor VIII (FVIII). The most efficient strategy to treat or prevent bleeding in patients with hemophilia A relies on replacement therapy using exogenous FVIII. Commercially available recombinant FVIII are produced using an expensive perfusion technology in stainless steel fermenters. A fed-batch fermentation technology was recently developed to produce 'Neureight', a full-length recombinant human FVIII, in Chinese hamster ovary (CHO) cells...
May 5, 2018: Cellular Immunology
https://www.readbyqxmd.com/read/29750671/successful-treatment-of-severe-menorrhagia-at-menarche-with-recombinant-factor-viia-in-an-adolescent-girl-with-type-iii-von-willebrand-s-disease
#13
Dilek Gurlek Gokcebay, Vildan Culha, Nese Yarali, Namik Yasar Ozbek
: Type III von Willebrand's disease (vWD) is an inherited bleeding disorder, which is frequently associated with menorrhagia in women. Treatment options include antifibrinolytics, desmopressin, von Willebrand factor/factor VIII concentrates and in intractable bleeding circumstances recombinant factor VIIa (rFVIIa). We present an adolescent case with type III vWD who had a menorrhagia at menarche that was refractory to the standard treatment and ultimately was treated with rFVIIa successfully.
May 9, 2018: Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis
https://www.readbyqxmd.com/read/29747832/modulatory-role-of-pulsatility-on-von-willebrand-factor-implications-for-mechanical-circulatory-support-associated-bleeding
#14
EDITORIAL
Juan J Badimon, Carlos G Santos-Gallego
No abstract text is available yet for this article.
May 15, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29747831/arterial-pulsatility-and-circulating-von-willebrand-factor-in-patients-on-mechanical-circulatory-support
#15
Flavien Vincent, Antoine Rauch, Valentin Loobuyck, Emmanuel Robin, Christoph Nix, André Vincentelli, David M Smadja, Pascal Leprince, Julien Amour, Gilles Lemesle, Hugues Spillemaeker, Nicolas Debry, Christian Latremouille, Piet Jansen, Antoine Capel, Mouhamed Moussa, Natacha Rousse, Guillaume Schurtz, Cédric Delhaye, Camille Paris, Emmanuelle Jeanpierre, Annabelle Dupont, Delphine Corseaux, Mickaël Rosa, Yoann Sottejeau, Svenja Barth, Claudia Mourran, Valérie Gomane, Augustin Coisne, Marjorie Richardson, Claudine Caron, Cristian Preda, Alexandre Ung, Alain Carpentier, Thomas Hubert, Cécile Denis, Bart Staels, Peter J Lenting, Eric Van Belle, Sophie Susen
BACKGROUND: The main risk factor for bleeding in patients with continuous-flow mechanical circulatory support (CF-MCS) is the acquired von Willebrand factor (VWF) defect related to the high shear-stress forces developed by these devices. Although a higher bleeding rate has been reported in CF-MCS recipients who had reduced pulsatility, the relation between pulsatility and the VWF defect has never been studied. OBJECTIVES: The purpose of this study was to investigate the relation between pulsatility and VWF under CF-MCS...
May 15, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29747114/effect-of-double-filtration-plasmapheresis-for-antibody-mediated-rejection-on-hemostasis-parameters-and-thrombin-generation
#16
R Marlu, P Malvezzi, L Seyve, T Jouve, J Maurizi, F Defendi, P L Carron, M Christophe, A Le Gouellec, B Polack, L Rostaing
INTRODUCTION: Donor-specific alloantibodies (DSAs) cause kidney-allograft loss in chronic antibody-mediated rejection (CAMR). Treatment relies on blocking antibody-producing cells and removing DSAs by apheresis: e.g., double-filtration plasmapheresis (DFPP). MATERIALS AND METHODS: To determine the impact of DFPP (6 or 8 sessions/patient) on clotting factors and natural anticoagulants, and on thrombin generation, we performed a prospective and observational study in five CAMR kidney-transplant patients who received DFPP plus rituximab therapy...
April 20, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29746258/gi-bleeding-during-cf-lvad-support-state-of-the-field
#17
Rachna Kataria, Ulrich P Jorde
Continuous-flow left ventricular assist devices (CF-LVADs) are increasingly used for the management of advanced heart failure refractory to optimal medical therapy. Despite the encouraging outcomes with CF-LVADs, gastrointestinal bleeding (GIB) continues to be a rather concerning complication resulting in increased rates of readmission and increased morbidity. The exact pathophysiology of CF-LVAD associated GIB remains poorly understood and this lack of knowledge limits our ability to control this morbid complication...
May 9, 2018: Cardiology in Review
https://www.readbyqxmd.com/read/29743402/-durable-remission-attained-with-rituximab-therapy-in-a-patient-with-acquired-von-willebrand-syndrome-associated-with-cd20-positive-lymphoproliferative-disorder
#18
Honami Kurahashi, Yoshinari Kawabata, Yoshihiro Michishita, Atsushi Kitabayashi, Takahiro Kobayashi, Akihiro Kitadate, Naoto Takahashi
A 61-year-old female with no history of bleeding was admitted to our hospital owing to persistent bleeding after the left knee joint injection and activated partial thromboplastin time prolongation. Subsequent coagulation tests revealed a critically declined level of the von Willebrand factor (VWF) antigen (<10%) and activity (<10%) measurement besides a significantly declined factor VIII activity (4%). Despite diagnosing her with acquired von Willebrand syndrome (AvWS) and managing her bleeding with desmopressin acetate hydrate (DDAVP), we could not precisely make a definitive diagnosis the underlying disorder...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/29742662/patterns-of-von-willebrand-disease-screening-in-girls-and-adolescents-with-heavy-menstrual-bleeding
#19
Amanda E Jacobson, Sara K Vesely, Terah Koch, Janis Campbell, Sarah H OʼBrien
OBJECTIVE: To estimate the frequency of von Willebrand disease screening and factors that affect screening frequency in a national sample of girls and adolescents with heavy menstrual bleeding. METHODS: In this retrospective cohort study, we used a national claims database for privately and publicly insured patients between 2011 and 2013 for girls aged 10-17 years. Diagnostic criteria of heavy menstrual bleeding were the presence of one inpatient or two outpatient International Classification of Diseases, 9th Revision codes for heavy menstrual bleeding...
May 7, 2018: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29742318/a-comparative-analysis-of-different-automated-von-willebrand-factor-glycoprotein-ib-binding-activity-assays-in-well-typed-von-willebrand-disease-patients
#20
I Vangenechten, K Mayger, P Smejkal, O Zapletal, J J Michiels, G W Moore, A Gadisseur
BACKGROUND: von Willebrand Disease (VWD) is an inherited bleeding disorder caused by quantitative (type 1, 3) or qualitative (type 2) von Willebrand factor (VWF) defect. VWD diagnosis and classification require numerous laboratory tests. VWF: Glycoprotein Ib (GPIb)-binding activity assays are used to distinguish type 1 from type 2 VWD. OBJECTIVES: Three different automated VWF:GPIb-binding activity assays were compared. PATIENTS AND METHODS: BC-VWF:RCo (Siemens Healthcare Diagnostics), HemosIL® VWF:RCo (Instrumentation Laboratory) and INNOVANCE® VWF:Ac (Siemens Healthcare Diagnostics) were performed in a well typed VWD cohort (n=142)...
May 9, 2018: Journal of Thrombosis and Haemostasis: JTH
keyword
keyword
113825
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"